OTT166 / Our initial therapeutic

Our initial therapeutic, OTT166, administered as an eye drop containing a novel RGD-binding integrin inhibitor, is in Phase 2 of clinical development to enable earlier intervention for diabetic retinopathy, a chronic, progressive disease that is one of the leading causes of vision loss in the United States. Our goal is to bring transformative treatments to clinicians and their patients who are consigned to “watch and wait” as disease progresses, ultimately requiring medically intensive and invasive therapy.